Chemomab Therapeutics Ltd. (CMMB) is scheduled to make presentations at the Annual Congress of the European Association for the Study of the Liver in Barcelona, Spain, on May 30, 2026.
This clinical-stage biotechnology company is developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Its lead drug candidate is Nebokitug, a first-in-class dual activity monoclonal antibody that neutralizes CCL24, a soluble protein that helps drive the inflammatory and fibrotic pathways central to primary sclerosing cholangitis and other fibro-inflammatory diseases.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.